



## Medroxyprogesterone Acetate 150 mg/mL Injectable Suspension (Depo-Provera)

**The Issue:** Due to the shortage of medroxyprogesterone acetate 150 mg/mL injectable suspension (vials) in Canada, Health Canada has approved the importation of US-labelled pre-filled syringes from Pfizer in order to prevent supply gaps until Canadian product is available again (likely mid 2022).

**Clinical Use:** Medroxyprogesterone acetate injectable suspension is mainly used as a contraceptive.

**Practice Implications:** Staff may see both the Canadian and US-labelled products in circulation during the shortage. The products are the same in terms of concentration (150 mg/mL), volume (1 mL), storage requirements (room temperature), and administration procedure.

- **\*REMINDER\*:** both products must be shaken vigorously before use to insure that the dose being administered represents a uniform suspension

For more information see communication from Pfizer:

[https://www.pfizer.ca/sites/default/files/202106/Signed\\_Final\\_DHCPL\\_Depo-Provera\\_28June2021\\_EN.pdf](https://www.pfizer.ca/sites/default/files/202106/Signed_Final_DHCPL_Depo-Provera_28June2021_EN.pdf)

### Product Comparison:

Canadian-Labelled Product: 150 mg/mL VIAL	US-Labelled Product: 150 mg/mL PRE-FILLED SYRINGE
Packaging Label (English and French): <b>*SHAKE VIGOROUSLY BEFORE USE*</b>	Packaging Label (English only): <b>*SHAKE VIGOROUSLY BEFORE USE*</b>
	  

<b>November 15, 2021</b> For the information of physicians, nurses, and pharmacists. <b>PLEASE POST</b>	<b>Drug Shortage</b>	✓	<b>For further information contact:</b> Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	<b>Drug Discontinuation</b>		
	<b>Medication Change</b>	✓	
	<b>Best Practice</b>		